首页> 外文期刊>British Journal of Clinical Pharmacology >Comparison of the effects of clonidine and yohimbine on pupillary diameter at different illumination levels.
【24h】

Comparison of the effects of clonidine and yohimbine on pupillary diameter at different illumination levels.

机译:比较可乐定和育亨宾对不同光照水平下瞳孔直径的影响。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: To evaluate the pupillary effects of single doses of the alpha2-adrenoceptor agonist clonidine and the alpha2-adrenoceptor antagonist yohimbine under several illumination conditions. METHODS: Sixteen healthy male volunteers received clonidine 0.2 mg, yohimbine 22 mg, clonidine 0.2 mg + yohimbine 22 mg in a double-blind placebo-controlled, cross-over study. 2 h post drug ingestion pupil diameter was recorded in darkness, and at luminance levels of 6 Cd m-2, 91 Cd m-2 and 360 Cd m-2. The effects of the active treatments on pupil diameter were also expressed as the differences from the placebo condition ('placebo-corrected' data; mean [95% CI]). RESULTS: Clonidine had little effect on pupil diameter in darkness; however, it caused a significant, light-dependent, miosis when the eye was illuminated. On the other hand yohimbine increased pupil size; this increase was significant at 91 and 360 Cd m-2. There were no significant differences between the effects of the combined treatment (clonidine 0.2 mg + yohimbine 22 mg) and the effect of placebo. CONCLUSIONS: The pupillary effects of clonidine and yohimbine are likely to reflect the interaction of these drugs with inhibitory alpha2-adrenoceptors located on central noradrenergic neurones, which in turn would lead to a decrease and an increase, respectively, in sympathetic outflow to the iris. The light dependence of the pupillary effects of these drugs, however, suggests that the parasympathetic light reflex pathway is also involved, which is known to be under inhibitory control from the central noradrenergic neurones. Modulation of parasympathetic outflow seems to play an important role since both drugs had relatively little effect on pupil diameter in darkness when sympathetic activity predominates.
机译:目的:在几种照明条件下,评估单剂量的α2-肾上腺素受体激动剂可乐定和α2-肾上腺素受体拮抗剂育亨宾对瞳孔的影响。方法:在双盲安慰剂对照,交叉研究中,十六名健康的男性志愿者接受可乐定0.2 mg,育亨宾22 mg,可乐定0.2 mg +育亨宾22 mg。吸食药物后2小时,在黑暗中以及在6 Cd m-2、91 Cd m-2和360 Cd m-2的亮度水平下记录瞳孔直径。积极治疗对瞳孔直径的影响还表示为与安慰剂状况的差异(“安慰剂校正”数据;平均值[95%CI])。结果:可乐定在黑暗中对瞳孔直径影响不大。但是,当眼睛被照亮时,它会导致明显的光依赖型瞳孔缩小。另一方面,育亨宾增加了瞳孔的大小。这种增加在91和360 Cd m-2时是显着的。联合治疗(可乐定0.2 mg +育亨宾22 mg)与安慰剂的作用之间无显着差异。结论:可乐定和育亨宾的瞳孔作用可能反映了这些药物与位于中央去甲肾上腺素能神经元上的抑制性α2-肾上腺素受体的相互作用,进而导致虹膜交感神经流出减少和增加。然而,这些药物对瞳孔作用的光依赖性表明,还牵涉到副交感神经反射途径,已知该途径受中央去甲肾上腺素能神经元的抑制。副交感神经流出的调节似乎起重要作用,因为当交感神经活动占主导时,这两种药物在黑暗中对瞳孔直径的影响相对较小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号